Acorda Therapeutics Inc (ACOR) Insider David Lawrence Sells 3,431 Shares of Stock

Acorda Therapeutics Inc (NASDAQ:ACOR) insider David Lawrence sold 3,431 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $31.74, for a total transaction of $108,899.94. Following the transaction, the insider now directly owns 4,993 shares in the company, valued at $158,477.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Lawrence also recently made the following trade(s):

  • On Friday, June 8th, David Lawrence sold 25,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $28.19, for a total transaction of $704,750.00.

Acorda Therapeutics traded down $0.15, hitting $31.50, during trading on Thursday, Marketbeat.com reports. 431,911 shares of the company’s stock traded hands, compared to its average volume of 630,411. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 30.29 and a beta of 1.63. The company has a quick ratio of 3.41, a current ratio of 3.65 and a debt-to-equity ratio of 0.61. Acorda Therapeutics Inc has a 1 year low of $16.55 and a 1 year high of $36.35.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.33 by ($0.19). The business had revenue of $106.17 million for the quarter, compared to analysts’ expectations of $130.94 million. Acorda Therapeutics had a negative net margin of 36.98% and a negative return on equity of 3.38%. The business’s quarterly revenue was down 11.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) earnings per share. analysts anticipate that Acorda Therapeutics Inc will post -1.11 EPS for the current fiscal year.

A number of brokerages have recently commented on ACOR. BidaskClub raised shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Oppenheimer set a $21.00 target price on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Monday. Piper Jaffray Companies raised shares of Acorda Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $25.10 to $37.00 in a research report on Thursday, February 15th. Zacks Investment Research raised shares of Acorda Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 24th. Finally, Cowen reaffirmed a “buy” rating and set a $30.00 target price on shares of Acorda Therapeutics in a research report on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have assigned a buy rating and two have given a strong buy rating to the stock. Acorda Therapeutics has a consensus rating of “Hold” and a consensus price target of $21.83.

A number of hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its holdings in Acorda Therapeutics by 5.7% during the first quarter. Dimensional Fund Advisors LP now owns 3,121,775 shares of the biopharmaceutical company’s stock valued at $73,830,000 after buying an additional 167,084 shares during the period. Northern Trust Corp increased its holdings in Acorda Therapeutics by 0.5% during the first quarter. Northern Trust Corp now owns 1,042,123 shares of the biopharmaceutical company’s stock valued at $24,647,000 after buying an additional 5,140 shares during the period. Millennium Management LLC increased its holdings in Acorda Therapeutics by 269.6% during the first quarter. Millennium Management LLC now owns 734,774 shares of the biopharmaceutical company’s stock valued at $17,377,000 after buying an additional 535,970 shares during the period. Spark Investment Management LLC increased its holdings in Acorda Therapeutics by 25.3% during the first quarter. Spark Investment Management LLC now owns 512,600 shares of the biopharmaceutical company’s stock valued at $12,122,000 after buying an additional 103,500 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in Acorda Therapeutics by 2.9% during the first quarter. Principal Financial Group Inc. now owns 367,973 shares of the biopharmaceutical company’s stock valued at $8,703,000 after buying an additional 10,536 shares during the period.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply